ABSTRACT
INTRODUCTION
Chronic myeloid leukaemia (CML) is now considered an indolent disease. This comes after imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced for the treatment of CML a decade ago. In fact, 90% of CML patients on imatinib mesylate treatment are still alive after five years.
(1) Furthermore, patients who achieve complete cytogenetic response (CCyR) and major molecular response (MMR) by 12 and 18 months, respectively, show a significantly better progression-free survival (PFS). (2) Nevertheless, there is still a substantial number of patients who do not achieve the desired response. An eight-year follow-up conducted in the Immediate Risk Stratification Improves Survival (IRIS)
trial showed that 37% of the patients on imatinib had an unfavourable outcome, with 32% of them failing to achieve CCyR or losing CCyR, and 5% of them being intolerant to imatinib.
Many studies have demonstrated that the achievement of early CCyR and MMR among imatinib-treated CML patients is associated with improved survival. (4) (5) (6) (7) Based on the findings of these studies, molecular response at defined time points is now widely accepted as a predictive marker for subsequent outcomes in CML patients. Second-generation TKIs, such as dasatinib, nilotinib and bosutinib, are more potent than imatinib, and have proven efficacy in patients who are resistant or intolerant to imatinib. (8, 9) More patients have achieved optimal cytogenetic and molecular responses when treated with these newer drugs than with imatinib.
Furthermore, the responses achieved using the newer drugs were faster and deeper, contributing to a lower rate of disease progression and superior long-term outcomes. (10) (11) (12) Both the National Comprehensive Cancer Network (NCCN) and the European LeukemiaNet (ELN) updated their guidelines to include BCR-ABL ≤ 10% as a treatment response milestone at three months. (13, 14) ELN defines optimal response as a BCR-ABL level Chicago, IL, USA) was used to process, manage and analyse the data to determine the factors that significantly affect the response rate, survival and frequency of adverse effects.
Frequencies and descriptive statistics were also generated using the same program.
Differences among the variables were evaluated using the Chi-squared test, and survival probabilities were estimated using Kaplan-Meier's method. A p-value < 0.05 was considered statistically significant.
RESULTS
A total of 70 patients -65 (92.9%) patients in chronic phase and 5 (7.1%) patients in accelerated phase -were included in the study (Table I) 
as median (interquartile range). CML: chronic myeloid leukaemia
The overall survival (OS) at ten years was 94.3% (Fig. 1) . The OS was significantly better among the patients who achieved CCyR than among those who did not (98.2% vs.
75.0%, p < 0.001) (Fig. 2 & Table II) . Similarly, the OS of the patients who achieved and maintained MMR was significantly better than those who did not (97.8% vs. 87.1%, p = 0.012) (Fig. 3) . When the patients were stratified according to when they achieved CCyR and MMR, the OS of the patients who achieved CCyR at or before 12 months was 100.0%, while the OS of those who achieved CCyR after 12 months was 95.8% (p = 0.637), and the OS of the patients who achieved MMR at or before 18 months was 100.0%, while the OS of those who achieved MMR after 18 months was 97.8% (p = 0.190).
Patients who had a BCR-ABL level ≤ 10% at six months had a significantly better OS than those who had a BCR-ABL level > 10% at six months (100.0% vs. 88.9%, p = 0.041) (Fig. 4) . However, BCR-ABL level at three months did not predict better OS; patients who had a BCR-ABL level ≤ 10% at three months did not have a significantly better OS than those who had a BCR-ABL level > 10% at three months (100.0% vs. 95.2%, p = 0.545).
There was no difference in the OS of patients who had < 1 log BCR-ABL reduction and those who had ≥ 1 log BCR-ABL reduction at 12 months (91.3% vs. 100.0%, p = 0.142). The ten-year event-free survival (EFS) among the 70 patients was 92.9%. The EFS was better among the patients who achieved CCyR and MMR than those who did not (CCyR:
96.4% vs. 73.0%, p = 0.002; MMR: 97.8% vs. 92.9%, p = 0.003). The EFS was also better among the patients who had a BCR-ABL level ≤ 10% at six months than those who had a BCR-ABL level > 10% at six months (100.0% vs. 82.4%, p = 0.013). There was no significant difference in the EFS of the patients who achieved MMR at 18 months and the EFS of those who did not (100.0% vs. 96.2%, p = 0.366). Similarly, the EFS of the patients who achieved CCyR at 12 months and those who did not did not differ significantly (100.0% vs. 91.7%, p = 0.319). On the other hand, we found that a < 1 log reduction of BCR-ABL at ABL at 12 months and the EFS for patients who had ≥ 1 log reduction of BCR-ABL at 12 months were 81.8% and 100.0%, respectively (p = 0.006).
DISCUSSION
The survival of patients with CML has improved significantly since the introduction of imatinib more than a decade ago. Early-phase CML patients receiving imatinib can have an almost-normal lifespan. The IRIS trial showed that the eight-year survival rate for CML patients on imatinib was 85%; the survival rate was even better (i.e. 93%) if only CMLrelated deaths were considered. (2, 3) In the present study, the patients on imatinib showed a similar excellent survival, with a median survival duration of 74 (range 15-197) months and an OS of 94.3%. In the IRIS trial, long-term follow-up of the patients also revealed that nearly all the patients who remained on imatinib achieved CCyR, and progression of the disease after the first three years of treatment was extremely rare. (2) In comparison, the percentage of CCyR and MMR among the patients in the present study were 80.0% and 65.7%, respectively; these values are comparable to other studies. (15, 16) The results of our study have proven that a good response also can be achieved in a real-life clinical setting.
Even though imatinib has been proven to have excellent efficacy, there are still a considerable number of patients who respond poorly to it. Therefore, many studies have been conducted to further improve the outcome of CML patients. Hehlmann et al compared imatinib at 800 mg per day, imatinib at 400 mg per day and imatinib at 400 mg per day plus interferon to determine if more intensive treatment would result in a better outcome. (17) The results of Hehlmann et al's study showed that patients on high-dose imatinib (i.e. 800 mg per day) had a significantly higher incidence of MMR at 12 months. However, the better responses did not translate to better OS and PFS at three years. (17) This observation was further confirmed in a systematic review and meta-analysis by Gafter-Gvili et al. (18) In that review of four randomised trials, the authors showed that CCyR and MMR at 12 months were improved by high-dose imatinib in patients with chronic-phase CML; however, there was no difference in the all-cause mortality or disease progression at the end of follow-up. (18) The results of the present study revealed that the patients who achieved CCyR and MMR had better OS and EFS as compared to those who failed to achieve these responses (Table I) .
However, the OS and EFS did not differ between the patients who attained CCyR at or before 12 months and those who attained CCyR after 12 months, and neither did the OS and EFS differ between the patients who attained MMR at or before 18 months and those who attained MMR after 18 months. This finding is in contrast to the findings of Hughes et al's study, (2) which showed that patients who achieved MMR at 18 months had a better EFS. This difference could be due to the small sample size (n = 70) of the present study.
In a retrospective analysis done on 1,440 newly diagnosed chronic-phase CML patients, the OS rates at five years were better among the patients who had a BCR-ABL level between 1% and 10% at three months (OS = 94%) and ≤ 1% (OS = 97%) at three months, as compared to the patients who had a BCR-ABL level > 10% at three months (OS = 87%). (19) In addition, a BCR-ABL level > 1% at six months was associated with inferior survival rates at five years when compared to a BCR-ABL level < 1% at six months (89% vs. 97%). (19) Jain et al published similar evidence from their single-centre experience with 483 newly diagnosed chronic-phase CML patients who received either 400 mg or 800 mg of imatinib, nilotinib or dasatinib as a first-line treatment. (20) The three-year failure-free survival (FFS) was better if the three-month BCR-ABL level was ≤ 1% and not between 1% and 10% or > 10% (FFS = 85%, 73% and 61%, respectively; p = 0.016). The three-year FFS for the patients with a six-month BCR-ABL level ≤ 1% was 89%, while it was 56% for patients with a BCR-ABL level between 1% and 10%, and 49% for those with a BCR-ABL level > 10% (p < 0.001). (20) The Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed patients (ENESTnd) study, which compared the use of nilotinib and imatinib in newly diagnosed chronic-phase CML patients, also reported correlations between BCR-ABL levels at three months, and PFS and OS by four years. (9) Similar results were seen in the DASatinib versus Imatinib Study In treatment-Naive CML patients (DASISION) trial, which compared the use of dasatinib and imatinib in newly diagnosed chronic-phase CML patients. (8) At the end of three years, better PFS and OS were observed in the patients with a three-month BCR-ABL level ≤ 10% than in the patients with a three-month BCR-ABL level > 10% (PFS: 93%
vs. 68%, p = 0.0003, OS: 96% vs. 86%, p = 0.03). (8) Marin et al identified that patients with a BCR-ABL level < 9.84% at three months and < 1.67% at six months had significantly higher eight-year OS than patients with higher transcript levels (93.3% vs. 56.9% and 93.7% vs.
74.7%, respectively). (21) In contrast, a BCR-ABL level > 10% at six months predicted a poorer survival in the patients in the present study; at six months, the OS for patients with a BCR-ABL level ≤ 10% and patients with a BCR-ABL level > 10% were 100.0% and 88.9%, respectively (p = 0.041). This finding is consistent with the results published by Klamová et al, which showed that patients with a BCR-ABL level < 10% at six months had better survival. (16) Furthermore, Hughes et al also proved that a BCR-ABL level > 10% at six months and a BCR-ABL level > 1% at 12 months predict inferior EFS and a higher rate of disease progression. (2) This observation is especially important for less developed countries, where the need to use higher dosages of imatinib or the need to change treatment from imatinib to newer generation TKIs (in order to achieve faster and deeper responses) would result in a significant financial burden.
The present study also revealed that ≥ 1 log reduction of BCR-ABL at 12 months predicts better EFS when compared to a < 1 log reduction of BCR-ABL at 12 months (100.0%
vs. 81.8%, p = 0.006), even though no significant difference was observed between the OS of these two groups (100% vs. 91.3%, p = 0.142).
Second-generation TKIs are more potent, and they induce faster and higher rates of CCyR and molecular responses. They have also recently been approved as first-line therapy.
While these newer TKIs show a trend of better PFS, there is no evidence to prove that OS is improved with these TKIs. (22) Imatinib is still advantageous since it is effective in a large proportion of patients. In addition, the safety profile of imatinib has been well established.
More importantly, the imminent availability of generic imatinib could potentially reduce the financial burden of long-term therapy for CML. This is crucial, especially in developing countries, as experts have argued that the prices for cancer treatment, with CML treatment as the example, are not sustainable. (23) In conclusion, the results of the present study show that imatinib is still a reasonable first-line therapy. However, vigilant monitoring of patients whose BCR-ABL level is > 10%
at six months of treatment should be implemented so that prompt action can be taken to provide the best outcome for these patients. 
